Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Allogene Therapeutics Inc.

www.allogene.com

Latest From Allogene Therapeutics Inc.

Servier To Tackle Parkinson's With Oncodesign Pact

A couple of years after Ipsen returned the rights to an LRRK2 Parkinson's program, Oncodesign has bagged a new partner in Servier and stands to bank up to €320m if all goes well.

Neurology Deals

Gene Therapy Investment At All Time High, Commercialization Challenges Noted

Investor appetite for cell and gene therapy companies has skyrocketed during the past year. However, storm clouds may gather as manufacturing and reimbursement challenges remain.

Regenerative Medicine Financing

AstraZeneca, Novartis Continued Divestment Sprees In 2018, While Peers Joined The Action

While leading large pharma with seven out-licensing or divestiture deals apiece during 2018, AstraZeneca and Novartis each slowed their pace somewhat. But several peer companies followed suit, as there were 31 such deals among the 20 largest biopharma firms last year.

 

Deals M & A

Finance Watch: Gossamer, Alector And Harpoon Launch First Biopharma IPOs Of 2019

Public Company Edition: Grossing $276m, Gossamer would have been the third-largest biopharma IPO in the US if it had launched last year. Also, recent public company financings include debt and follow-on offerings; and two more firms cut jobs – Capricor and Seres.

Financing Business Strategies
See All

Company Information

  • Industry
  • Biotechnology
    • Gene Therapy, Cell Therapy
  • Pharmaceuticals
    • Vaccines
  • Therapeutic Areas
  • Cancer
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Company Type
  • Start-Up
  • Parent & Subsidiaries
  • Allogene Therapeutics Inc.
  • Senior Management
  • David Chang, MD, PhD, Pres. & CEO
    Eric Schmidt, PhD, CFO
    Susie Jun, MD, PhD, Chief Dev. Officer
  • Contact Info
  • Allogene Therapeutics Inc.
    270 Littlefield Ave.
    South San Francisco, CA 94080
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register